* Akcea Therapeutics Inc - We are on track for a potential global commercial launch of volanesorsen in 2018

* Akcea Therapeutics Inc - Akcea plans to file for marketing authorization for volanesorsen to treat FPL in 2019 if data from BROADEN study are positive Source text for Eikon: Further company coverage: